OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy ...

Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Cambridge, Massachusetts Friday, October 24, 2025, 18:00 Hrs [IST] ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Professor Guan Xinyuan (left) and his research team developed the 'Cancer Immunology Data Engine', which is publicly ...

Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and ...

Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.